Target Price | $34.68 |
Price | $12.30 |
Potential |
181.95%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target REGENXBIO, Inc. 2026 .
The average REGENXBIO, Inc. target price is $34.68.
This is
181.95%
register free of charge
$54.60
343.90%
register free of charge
$14.14
14.96%
register free of charge
|
|
A rating was issued by 19 analysts: 17 Analysts recommend REGENXBIO, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2026 of
181.95%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 83.33 | 253.14 |
7.66% | 203.78% | |
EBITDA Margin | -256.97% | -12.03% |
7.55% | 95.32% | |
Net Margin | -272.53% | -49.15% |
6.66% | 81.97% |
15 Analysts have issued a sales forecast REGENXBIO, Inc. 2025 . The average REGENXBIO, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2025. The average REGENXBIO, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 REGENXBIO, Inc. Analysts have issued a net profit forecast 2025. The average REGENXBIO, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.59 | -2.47 |
23.75% | 46.19% | |
P/E | negative | |
EV/Sales | 1.18 |
15 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. EPS is
This results in the following potential growth metrics and future valuations:
REGENXBIO, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 08 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Sep 08 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 08 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.